The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version (PDF) or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 524 KB) and Technical Notes (PDF, 762 KB) pages.


Download and Print: Download Printer-friendly PDF Download data

Table 1.22

U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2012a Using Different Tumor Inclusion Criteriab
Site Sex 5-Year Limited Duration Prevalence 37-year Limited Duration Prevalence
1st Invasive
Tumor Everc		 1st Per Site in
Previous 37 Yearsd		 1st Per Site in
Previous 5 Yearse		 1st Invasive
Tumor Everc		 1st Per Site in
Previous 37 Yearsd
All Sites Both Sexes 4,660,390 4,751,475 5,238,866 13,405,317 13,624,510
Male 2,395,057 2,430,935 2,669,928 6,387,558 6,462,521
Female 2,265,333 2,320,540 2,568,938 7,017,759 7,161,989
Oral Cavity & Pharynx Both Sexes 108,762 126,337 131,109 282,380 312,792
Male 76,856 88,637 91,609 188,848 207,488
Female 31,906 37,700 39,500 93,532 105,304
Esophagus Both Sexes 21,344 26,589 26,680 35,667 42,388
Male 16,607 20,581 20,639 27,750 32,814
Female 4,737 6,008 6,041 7,917 9,574
Stomach Both Sexes 37,369 45,065 45,492 75,640 87,222
Male 22,014 27,032 27,269 43,300 50,402
Female 15,355 18,033 18,223 32,340 36,820
Colon & Rectum Both Sexes 398,737 458,984 468,251 1,149,814 1,279,479
Male 204,170 234,705 239,034 573,302 635,108
Female 194,567 224,279 229,217 576,512 644,371
Liver & Intrahepatic Bile Duct Both Sexes 36,620 41,939 41,976 50,271 56,613
Male 27,039 30,599 30,620 35,990 40,166
Female 9,581 11,340 11,356 14,281 16,447
Pancreas Both Sexes 34,042 41,747 41,771 45,432 54,507
Male 17,628 21,807 21,819 22,666 27,478
Female 16,414 19,940 19,952 22,766 27,029
Larynx Both Sexes 31,457 37,206 37,786 87,479 98,015
Male 25,542 30,220 30,728 70,303 78,592
Female 5,915 6,986 7,058 17,176 19,423
Lung & Bronchus Both Sexes 233,827 301,827 311,522 402,326 498,404
Male 107,351 140,977 144,670 180,530 225,061
Female 126,476 160,850 166,852 221,796 273,343
Melanoma of the Skin Both Sexes 285,569 326,073 342,024 962,438 1,041,311
Male 153,364 179,735 189,728 478,737 525,778
Female 132,205 146,338 152,296 483,701 515,533
Breast Female 872,541 944,632 1,005,580 2,928,546 3,104,561
Cervix Female 39,323 41,561 41,655 214,008 220,136
Corpus & Uterus, NOS Female 183,434 205,521 205,655 598,766 653,998
Ovaryf Female 59,878 68,736 68,817 177,706 199,493
Prostate Male 1,044,262 1,128,141 1,128,224 2,794,570 2,976,626
Testis Male 42,435 43,354 44,013 218,903 221,980
Urinary Bladder Both Sexes 201,191 253,322 258,716 567,531 664,041
Male 153,198 193,786 198,124 424,112 496,868
Female 47,993 59,536 60,592 143,419 167,173
Kidney & Renal Pelvis Both Sexes 154,353 188,076 190,370 365,660 427,078
Male 94,867 117,507 119,055 217,927 257,221
Female 59,486 70,569 71,315 147,733 169,857
Brain & Nervous System Both Sexes 45,479 48,676 49,045 136,100 140,756
Male 24,643 26,423 26,633 72,270 74,764
Female 20,836 22,253 22,412 63,830 65,992
Thyroid Both Sexes 185,714 207,444 208,227 563,884 604,543
Male 40,645 47,892 48,044 121,802 134,236
Female 145,069 159,552 160,183 442,082 470,307
Hodgkin Lymphoma Both Sexes 38,167 40,722 40,777 176,990 181,967
Male 20,781 22,226 22,270 91,797 94,359
Female 17,386 18,496 18,507 85,193 87,608
Non-Hodgkin Lymphoma Both Sexes 205,597 242,575 245,938 541,393 606,972
Male 110,512 131,592 133,324 284,672 319,941
Female 95,085 110,983 112,614 256,721 287,031
Myeloma Both Sexes 56,508 67,424 67,605 89,416 103,463
Male 30,245 36,895 36,980 47,990 56,338
Female 26,263 30,529 30,625 41,426 47,125
Leukemia Both Sexes 120,252 139,986 140,426 312,923 345,422
Male 70,027 82,564 82,799 177,810 197,506
Female 50,225 57,422 57,627 135,113 147,916
Acute Lymphocytic Leukemia Both Sexes 17,081 17,590 17,590 71,898 72,647
Male 9,480 9,693 9,693 39,375 39,666
Female 7,601 7,897 7,897 32,523 32,981
Childhood (Ages 0-19) Both Sexes 65,893 65,980 66,533 326,769 327,259
Male 34,508 34,555 34,858 167,928 168,153
Female 31,385 31,425 31,675 158,841 159,106
Kaposi Sarcoma Both Sexes 7,384 7,975 7,975 26,300 27,684
Male 6,836 7,367 7,367 24,829 26,079
Female 548 608 608 1,471 1,605
Mesothelioma Both Sexes 3,247 4,116 4,116 4,957 5,962
Male 2,341 2,982 2,982 3,042 3,748
Female 906 1,134 1,134 1,915 2,214

Footnotes:

a U.S. 2012 cancer prevalence counts are based on 2012 cancer prevalence proportions from the SEER 9 registries and 1/1/2012 U.S. population estimates based on the average of 2011 and 2012 population estimates from the U.S. Bureau of the Census.

b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion which are listed in footnotes (c) to (e).

c First invasive tumor ever. Referred to as method (c) in Example below.

d First invasive tumor for each cancer site diagnosed during the previous 37 years (1975-2011). All sites is treated as a separate cancer "site". Referred to as method (d) in Example below.

e First invasive tumor for each cancer site diagnosed during the previous 5 years (2007-2011). All sites is treated as a separate cancer "site". Referred to as method (e) in Example below.

Example: Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2007; Melanoma in 2008.
In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 37-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2012.
In method (d) the 1981 melanoma is counted for the melanoma and all sites 37-year limited duration prevalence. The 2007 breast cancer is counted for the breast 5-year and 37-year limited duration prevalence.
In method (e) the 2007 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2008 melanoma is counted for 5-year limited duration prevalence for melanoma.

f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.